patient
acut
influenzalik
ill
ili
enrol
stanford
hospit
clinic
influenza
season
nasopharyng
swab
test
stanford
hospit
virolog
laboratori
esensor
respiratori
viral
panel
genmark
identifi
infect
viru
blood
sampl
collect
time
enrol
comparison
healthi
volunt
age
year
particip
influenza
vaccin
studi
stanford
univers
n
n
influenza
season
includ
studi
volunt
receiv
dose
iiv
fluzon
sanofi
pasteur
intramuscular
inject
none
subject
receiv
monoval
vaccin
volunt
random
receiv
intramuscular
iiv
intraderm
iiv
fluzon
intraderm
sanofi
pasteur
none
subject
receiv
season
influenza
vaccin
subset
particip
avail
particip
studi
n
reenrol
receiv
dose
season
iiv
rout
prior
immun
iiv
formul
contain
influenza
viru
strain
like
viru
like
viru
viru
iiv
contain
like
viru
like
viru
viru
serum
collect
day
vaccin
measur
level
neutral
antibodi
influenza
viru
neutral
assay
previous
describ
blood
sampl
collect
day
vaccin
ppab
studi
studi
approv
stanford
institut
review
board
written
inform
consent
obtain
particip
b
cell
isol
blood
sampl
use
rosettesep
human
bcell
enrich
cocktail
stemcel
technolog
cultur
collect
ppab
enzymelink
immunosorb
assay
elisa
perform
describ
previous
brief
plate
greiner
coat
purifi
coldadapt
influenza
kindli
provid
dr
h
jin
medimmun
vaccin
fluoresc
focu
form
unit
per
well
recombin
ha
cell
immun
technolog
matrix
protein
escherichia
coli
immun
technolog
nucleoprotein
np
insect
cell
imgenex
plate
block
incub
serial
dilut
ppab
start
dilut
well
incub
complet
medium
without
human
immunoglobulin
use
determin
background
plate
wash
incub
peroxidaseconjug
goat
g
igg
antibodi
goat
iga
antibodi
kpl
develop
tmb
substrat
kpl
measur
background
subtract
area
curv
auc
serial
dilut
sampl
calcul
describ
elsewher
hypothesi
test
use
pairedsampl
test
indic
comparison
immun
prime
influenza
viru
infect
versu
iiv
immun
data
set
compar
particip
common
comparison
mean
use
perturb
resampl
bia
correct
estim
p
valu
sequenti
bonferroni
adjust
use
adjust
multipl
comparison
across
hypothesi
test
figur
analys
perform
sa
v
sa
institut
code
avail
upon
request
hypothesi
test
declar
statist
signific
p
influenza
season
enrol
patient
acut
ili
tabl
includ
patient
infect
infect
influenza
b
viru
infect
metapneumoviru
infect
coronaviru
blood
sampl
collect
enrol
day
day
onset
ill
ppab
deriv
sampl
test
elisa
bind
reactiv
figur
control
use
pool
ppab
deriv
blood
sampl
collect
day
vaccin
group
recipi
iiv
contain
bind
detect
ppab
pool
iiv
recipi
individu
ppab
sampl
patient
present
day
later
symptom
onset
figur
bind
detect
ppab
sampl
collect
patient
day
patient
infect
influenza
b
viru
metapneumoviru
coronaviru
ppab
sampl
patient
bind
activ
igg
significantli
higher
iga
p
pair
test
result
suggest
patient
infect
substanti
virusspecif
plasmablast
respons
detect
blood
day
symptom
onset
igg
respons
domin
next
examin
igg
bind
ppab
individu
influenza
viru
protein
ha
np
influenza
substanti
bind
ha
detect
ppab
sampl
patient
figur
npspecif
bind
detect
patient
sampl
wherea
bind
detect
contrast
iiv
ppab
pool
bound
ha
antigen
np
ppab
influenza
b
patient
bind
influenza
viru
protein
figur
compar
ppab
reactiv
influenza
viru
protein
patient
group
iiv
recipi
sinc
precis
kinet
peripher
plasmablast
respons
influenza
viru
infect
known
observ
reactiv
ppab
sampl
collect
differ
day
diseas
onset
might
repres
peak
plasmablast
respons
therefor
instead
compar
reactiv
influenza
viru
protein
directli
normal
np
bind
activ
ha
reactiv
sinc
ha
primari
antigen
target
iiv
normal
reactiv
provid
inform
rel
pattern
ppab
respons
differ
influenza
viru
protein
shown
figur
normal
np
reactiv
significantli
higher
patient
iiv
recipi
mean
normal
bind
activ
also
higher
infect
patient
iiv
recipi
differ
statist
signific
perhap
small
sampl
size
larg
variabl
among
infect
patient
taken
togeth
result
indic
addit
bcell
respons
variabl
ha
patient
infect
develop
bcell
respons
conserv
np
significantli
higher
mount
iiv
recipi
despit
fact
iiv
prepar
contain
larg
amount
np
test
ppab
sampl
patient
iiv
recipi
abil
bind
fulllength
ha
protein
influenza
viru
strain
homotyp
infect
strain
heterovari
strain
heterosubtyp
avian
strain
peptid
ppab
sampl
detect
bind
also
bound
figur
addit
ppab
bound
portion
contain
conserv
major
antigen
site
stalk
domain
agreement
previou
report
iiv
ppab
pool
also
bound
heterovari
result
indic
crossreact
ppab
respons
heterovari
heterosubtyp
induc
patient
acut
infect
crossreact
part
mediat
bind
conserv
ha
stalk
domain
next
normal
reactiv
homotyp
reactiv
compar
normal
crossreact
ppab
infect
iiv
immun
group
shown
figur
normal
reactiv
significantli
higher
infect
patient
iiv
recipi
indic
plasmablast
respons
influenza
viru
infect
greater
rel
crossreact
heterovari
heterosubtyp
induc
iiv
analysi
identifi
subset
individu
age
year
receiv
monoval
vaccin
selfreport
cohort
healthi
iiv
recipi
pandem
individu
younger
year
littl
serum
antibodi
time
enrol
individu
detect
serum
neutral
antibodi
geometr
mean
titer
rang
suggest
previous
infect
wildtyp
seventeen
subject
seroneg
titer
lower
individu
immun
first
time
trival
iiv
either
intramuscular
intraderm
inject
note
detect
differ
frequenc
vaccinespecif
antibodi
secret
cell
vaccinespecif
ppab
reactiv
observ
sampl
patient
vaccin
intramuscularli
versu
vaccin
intraderm
data
shown
iiv
year
ident
strain
composit
contain
compon
compar
bcell
respons
iiv
immun
baselin
individu
measur
ppab
reactiv
homotyp
heterovari
heterosubtyp
protein
signific
differ
detect
bind
seroneg
seroposit
individu
figur
suggest
previou
natur
infect
result
detect
differ
plasmablast
respons
homotyp
heterovari
iiv
immun
note
mean
ppab
bind
homotyp
higher
seroposit
individu
seroneg
individu
although
differ
longer
signific
adjust
multipl
comparison
subsequ
influenza
season
iiv
recipi
receiv
iiv
contain
compon
comparison
respons
first
versu
second
iiv
immun
assess
ppab
reactiv
ha
protein
reflect
prime
effect
inactiv
vaccin
first
immun
bcell
respons
subsequ
vaccin
vaccin
second
immun
ppab
reactiv
significantli
lower
second
iiv
immun
first
immun
figur
agreement
result
level
serum
neutral
antibodi
increas
significantli
first
second
iiv
immun
foldincreas
titer
second
immun
significantli
lower
first
supplementari
data
therefor
prime
inactiv
vaccin
reduc
plasmablast
respons
subsequ
immun
vaccin
final
compar
fold
differ
ppab
reactiv
seroneg
seroposit
subject
figur
fold
differ
first
second
iiv
immun
figur
differ
repres
prime
effect
infect
versu
inactiv
immun
respect
shown
figur
prime
effect
significantli
differ
ppab
reactiv
taken
togeth
result
show
prime
inactiv
infect
result
significantli
reduc
plasmablast
respons
subsequ
immun
inactiv
vaccin
observ
vigor
bcell
respons
patient
acut
infect
demonstr
broad
ppab
reactiv
select
structur
protein
deriv
heterovari
strain
heterosubtyp
avian
strain
compar
bcell
respons
iiv
recipi
influenza
viru
infect
elicit
greater
bcell
respons
conserv
np
well
heterovari
heterosubtyp
also
identifi
distinct
prime
effect
infect
versu
iiv
immun
wildtyp
infect
affect
antigen
recal
respons
subsequ
immun
iiv
contain
strainspecif
ha
wherea
iiv
immun
result
significantli
reduc
homotyp
crossreact
ppab
respons
subsequ
immun
iiv
strain
day
vaccin
either
iiv
laiv
unpublish
data
specif
plasmablast
reach
peak
concentr
circul
recent
human
challeng
studi
wildtyp
influenza
viru
virusspecif
plasmablast
detect
day
infect
studi
howev
examin
kinet
infectioninduc
plasmablast
respons
antibodi
specif
plasmablast
kinet
bcell
respons
natur
infect
patient
like
variabl
kinet
volunt
receiv
standard
vaccin
experiment
challeng
wildtyp
influenza
viru
prepar
prespecifi
time
dose
supposit
support
report
plasmablastderiv
influenza
monoclon
antibodi
isol
influenza
patient
day
onset
symptom
current
studi
detect
substanti
ppab
respons
infect
patient
sever
day
onset
symptom
although
multipl
sampl
perform
identifi
peak
day
limit
current
studi
lack
random
comparison
infect
versu
vaccin
individu
seroneg
versu
seroposit
individu
small
number
wide
age
rang
underli
diseas
infect
patient
examin
elderli
patient
patient
substanti
ppab
reactiv
np
ha
differ
respons
younger
patient
previous
report
weaker
plasmablast
respons
elderli
subject
younger
individu
immun
iiv
ha
primari
antigen
compon
vaccin
clear
whether
lack
detect
haspecif
ppab
reactiv
elderli
patient
due
offpeak
sampl
collect
gener
reduc
haspecif
respons
thu
suggest
kinet
plasmablast
respons
includ
quantit
qualit
characterist
diseas
cours
address
futur
studi
defin
subject
popul
experiment
challeng
wildtyp
viru
addit
plasmablast
specif
ha
antigen
infect
viru
natur
infect
elicit
greater
plasmablast
respons
conserv
np
heterovari
strain
avian
strain
iiv
immun
recent
report
laiv
also
induc
proport
greater
plasmablast
respons
np
variant
ha
protein
iiv
find
suggest
laiv
immun
recapitul
distinct
qualit
characterist
wildtyp
influenza
viru
infect
term
bcell
respons
much
lower
magnitud
thu
wildtyp
influenza
viru
laiv
may
induc
protect
immun
similar
mechan
distinct
iiv
note
propos
antibodi
target
conserv
viru
compon
includ
stalk
domain
ha
group
influenza
virus
np
potenti
basi
univers
influenza
vaccin
would
offer
protect
broad
rang
season
pandem
influenza
virus
consist
data
show
laiv
superior
iiv
induc
crossprotect
basi
differ
bcell
respons
influenza
viru
infect
iiv
immun
current
unknown
address
futur
studi
includ
analys
immunoglobulin
gene
sequenc
antibodi
function
activ
bcell
repertoir
clonal
level
also
cours
tcell
respons
elucid
differ
aspect
immun
respons
natur
influenza
viru
infect
identifi
immun
correl
protect
immun
import
develop
nextgener
influenza
vaccin
recent
influenza
cohort
studi
reveal
high
rate
asymptomat
natur
influenza
viru
infect
commun
infect
detect
strainspecif
seroconvers
interest
determin
whether
asymptomat
influenza
viru
infect
differ
symptomat
case
immun
laiv
term
protect
immun
respons
determin
factor
affect
outcom
symptomat
vs
asymptomat
natur
infect
inform
could
lead
new
approach
influenza
vaccin
develop
base
reduc
influenza
pathogen
preserv
immunogen
repeat
exposur
influenza
viru
infect
vaccin
bcell
respons
influenza
vaccin
antigen
recal
respons
almost
individu
except
young
children
naiv
influenza
viru
infect
vaccin
activ
antigenspecif
b
cell
occur
germin
center
lymphoid
tissu
help
antigenspecif
follicular
helper
tcell
result
gener
plasmablast
switch
memori
b
cell
express
highaffin
antibodi
exposur
newli
emerg
strain
prime
strainspecif
b
cell
tcell
gener
memori
cell
turn
alter
bcell
respons
subsequ
vaccin
infect
current
studi
show
prime
iiv
result
diminish
strainspecif
recal
respons
subsequ
iiv
immun
wherea
suppress
observ
individu
prior
natur
infect
laiv
immun
also
result
detect
differ
serum
antibodi
plasmablast
respons
iiv
laiv
immun
subsequ
year
recent
studi
found
immun
live
attenu
avian
influenza
vaccin
stimul
virtual
serum
antibodi
effect
prime
immun
system
result
robust
serum
antibodi
respons
subsequ
immun
inactiv
vaccin
includ
broader
crossreact
compar
repeat
immun
inactiv
vaccin
alon
mice
prime
antigen
second
immun
epitopematch
tcell
independ
antigen
result
induct
toler
memori
b
cell
rather
recal
respons
substanti
tcell
respons
detect
volunt
experiment
infect
wildtyp
influenza
virus
anoth
human
studi
specif
subset
follicular
helper
tcell
correl
induct
antibodi
iiv
previous
prime
individu
naiv
subject
thu
defici
magnitud
function
properti
tcell
repertoir
specif
iiv
like
contribut
factor
reduc
bcell
respons
repeat
iiv
immun
efficaci
repeat
iiv
immun
issu
debat
time
howev
controversi
previous
focus
specif
gener
humor
immun
recipi
repeat
iiv
immun
comparison
previous
prime
natur
infect
sinc
annual
immun
iiv
common
practic
implic
find
longterm
effect
influenza
vaccin
need
care
evalu
especi
context
maxim
protect
immun
vulner
popul
elderli
individu
